Narcolepsy type 1 (NT1) is a neurological disorder characterized by excessive daytime sleepiness, cataplexy, sleep paralysis, and hallucinations while awake. It results from the loss of orexin-producing neurons in the hypothalamus, leading to a deficiency of the neuropeptide orexin/hypocretin. Studies show differences in the clinical presentation of NT1 between Caucasian and African American populations, highlighting the importance of research into genetic and clinical characteristics specific to Black and North African populations.
A genetic study in these populations could identify novel genes associated with NT1 and NT2, providing crucial information for personalized diagnosis and treatment. This would fill a knowledge gap and promote more effective interventions for individuals of African descent, contributing to a better understanding of narcolepsy globally.
Individuals of black and North African origin diagnosed with NT1 or NT2.
Age ≥ 6 years
Clinical confirmation of narcolepsy according to the criteria of the International Classification of Sleep Disorders (ICSD-3).
Signature of informed consent by the adult patient or both holders of parental authority for minor patients.
Individuals unable to understand the protocol or unwilling to participate.
Narcolepsy patients with NT1 or NT2.
Case-control
Prospective
saliva sampling
Geneticsaliva sampling
Describe the genetic and clinical features of type 1 and 2 narcolepsy in Black and North African populations
Presence of genetic specificity in the populations studied
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
